



Current Advances in the Development of SARS-CoV-2 Vaccines

Guest Editors:

Dr. Steven B. Bradfute

Center for Global Health, Division
of Infectious Diseases,
Department of Internal Medicine,
University of New Mexico,
Albuquerque, NM 505, USA

Dr. Scott Anthony

National Institute of Allergy and
Infectious Diseases (NIAID),
Frederick, MD, USA

Deadline for manuscript
submissions:

closed (15 September 2021)

Message from the Guest Editors

The ongoing SARS-CoV-2 pandemic has highlighted the need for rapid development, testing, distribution, and analysis of additional coronavirus vaccines. We are publishing this special issue to address these and many additional remaining questions for this pandemic. The appearance of multiple novel variants that exhibit the capacity to cause enhanced spread, pathogenesis, and/or evade prior immunological protection, with the added contribution of a strong potential for the emergence of additional novel variants, make it clear that additional vaccination and therapeutic efforts will be needed to resolve this pandemic. This special issue calls for submissions for manuscripts regarding many aspects of vaccines for SARS-CoV-2, including but not limited to:

- Duration of immunity
- Correlates of immunity
- Mechanisms of immunity
- Animal model development for testing SARS-CoV-2 vaccines
- Novel vaccines
- Adjuvants to improve vaccination
- Improvements in manufacturing and distribution of vaccines
- Optimal timing, routes or dosing of vaccinations





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)